^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abiraterone acetate

    i
    Other names: CB 7630, JNJ-212082, CB-7630, CB7630, BR9004
    Company:
    Generic mfg.
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    8d
    A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients (clinicaltrials.gov)
    P=N/A, N=1247, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    carboplatin • docetaxel • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Provenge (sipuleucel-T)
    10d
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Terminated, M.D. Anderson Cancer Center | Trial completion date: Apr 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)
    12d
    Distinct Expression Patterns and Clinical Associations of the IRX Gene Family Across Hormone-Sensitive Cancers. (PubMed, Cancers (Basel))
    In addition, IRX6 expression showed associations with reduced sensitivity to abiraterone, suggesting a potential link with therapeutic resistance in these tumours. Collectively, these findings highlight the context-dependent expression patterns and clinical associations of IRX genes across hormone-driven cancers. While largely correlative, this study provides a framework for future functional investigations and suggests that selected IRXs may have potential utility as biomarkers for disease stratification and treatment response in hormone-sensitive cancers.
    Journal
    |
    ER (Estrogen receptor) • AR (Androgen receptor) • IRX2 (Iroquois Homeobox 2) • IRX5 (Iroquois Homeobox 5)
    |
    abiraterone acetate
    18d
    CAMO959A12103: A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA-positive prostate cancer that has spread to other parts of the body.athway inhibitor (ARPI) in adults with PSMA-positive prostate cancer that has spread to other parts of the body. (2025-521859-23-00)
    P1/2, N=61, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Firmagon (degarelix) • Orgovyx (relugolix)
    18d
    CO45813: A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (2025-521327-67-00)
    P1/2, N=8, Not yet recruiting, F. Hoffmann-La Roche AG
    New P1/2 trial
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Itovebi (inavolisib)
    19d
    Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    20d
    DynaMO: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • apalutamide
    23d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    26d
    CHOMP: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, VA Office of Research and Development | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Checkpoint inhibition • Mismatch repair
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • PMS1 (PMS1 protein homolog 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • abiraterone acetate
    26d
    Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Provenge (sipuleucel-T)
    27d
    PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor. (PubMed, Cancers (Basel))
    Overall, the results indicate that maintaining Abiraterone treatment in combination with PARPis after resistance develops provides superior therapeutic efficacy compared to PARP inhibition alone, offering a promising strategy for managing Abiraterone-resistant prostate cancer. Combining Abiraterone with PARPis enhances therapeutic efficacy and overcomes the acquired insensitivity in mCRPC with BRCA1/2 or HRR mutations. These results support continued use of PARPis with Abiraterone to improve clinical outcomes.
    Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Lynparza (olaparib) • Zejula (niraparib) • abiraterone acetate
    29d
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)